admin

admin
Business

Benchmark reboots its Datadog target as the AI super cycle builds

Benchmark raised its price target on Datadog to $330 from $260 on Thursday, July 2, a Street high, while keeping its buy rating

Read More
Business

Your wallet is being put in danger by OpenAI

OpenAI is now worth $852 billion. The people who built that valuation are a small group of venture capitalists, early employees, and institutional

Read More
Business

Palantir doubles down on national security with Nvidia AI alliance

Palantir Technologies is betting big on a simple idea: The U.S. government should never have to depend on someone else’s AI model to

Read More
Business

Apple’s 2027 hardware refresh sends Wall Street a warning 

Apple (AAPL) is reportedly prepping for a 2027 hardware push that will go beyond the usual chip refresh. The Cupertino giant is testing

Read More
Business

Kroger just shook up the supermarket landscape

Kroger Co (KR) agreed on Wednesday, July 1, to acquire Giant Eagle, the family-owned grocery and pharmacy chain based in Pittsburgh, according to

Read More
Business

Palantir CEO gets painfully honest about AI’s biggest problem

Palantir (PLTR) CEOAlex Karp just pitched the company’s next big AI moment as a trust crisis. In a fresh television appearance on CNBC’s

Read More
Business

Nvidia stock catalyst the market is missing

Investors seem to be missing or misunderstanding the key details of Nvidia’s long-term strategy. We can see this in the stock’s performance. Nvidia

Read More
Business

Fresh lawsuit drops bombshell on Micron stock price

Micron Technology just delivered the best quarter in its history. However, three days later, a federal courtroom in California turned that story upside

Read More
Business

5-star analyst sets bold SpaceX stock price target

It didn’t take long for SpaceX (SPCX) to turn from hype to a disappointing IPO. The stock is trading near $161 at the

Read More
Business

Jim Cramer turns bullish on health care stock after years of doubt

For most of the past three years, Jim Cramer kept his distance from Moderna, treating the biotech stock with skepticism bordering on avoidance.

Read More